Immunohistochemistry (IHC) Market Study Explores Industry Growth Toward $4.47 Billion

The immunohistochemistry (IHC) market is on track for significant expansion in the coming years, driven by advancements in diagnostic technologies and growing demand for precision medicine. As this field evolves, new innovations and rising investments are set to shape the future landscape of IHC applications and tools.

Projected Market Size and Growth Trajectory of the Immunohistochemistry (IHC) Market
The immunohistochemistry market is forecasted to reach a valuation of $4.47 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.1%. Several factors contribute to this growth, including heightened demand for precision oncology diagnostics, increased use of AI-powered pathology analysis, growth in biomarker-driven drug development, and the expanding application of multiplex tissue profiling. Additionally, significant investments in advanced pathology infrastructure are propelling the market forward. Key trends during the forecast period include broader adoption of automated IHC staining systems, a rise in multiplex IHC techniques, integration of digital pathology platforms, growing companion diagnostic applications, and a stronger emphasis on antibodies with high specificity.

Download a free sample of the immunohistochemistry (ihc) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9267&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players Driving the Immunohistochemistry (IHC) Market Forward
Several prominent companies dominate the IHC market, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Merck Group, Danaher Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Bio SB Inc., Agilent Technologies Inc., Abcam plc, Takara Bio Inc., Biocare Medical LLC, Bio-Genex Laboratories, Diagnostic BioSystems Inc., PHC Holdings Corporation, Leica Biosystems, Vector Laboratories, Ionpath Inc., Reveal Biosciences, Akrivis Technologies Private Limited, LifeSpan BioSciences Inc., Enzo Life Sciences Inc., Epitomics Inc., and GenScript Biotech.
In a significant move in December 2023, Danaher Corporation, a US-based life sciences and diagnostics giant, acquired UK-based Abcam plc for an undisclosed amount. This acquisition aims to expand Danaher's life science reagents and consumables portfolio, enhance research and diagnostic protein tools, accelerate growth within the life sciences ecosystem, and strengthen its global presence in delivering integrated solutions to researchers and clinicians. Abcam plc is known for its expertise in antibodies, reagents, assays, and immunohistochemistry products.

Emerging Technologies Shaping the Future of the Immunohistochemistry (IHC) Market
Market leaders are now prioritizing innovation to improve diagnostic accuracy using cutting-edge technologies and high-quality reagents. A noteworthy advancement is the Neoflex multiomics mass spectrometry imaging (MSI) system, a sophisticated platform designed for precise tissue analysis. This system enables researchers to bridge the gap between discovery and clinical applications through high-resolution mass spectrometry that spatially maps biomolecules within tissue samples.
For example, in June 2024, Bruker Corporation, a US-based scientific instrument and diagnostic solution developer, launched the MALDI-TOF/TOF Neoflex Imaging Profiler. This mass spectrometry-based tissue imaging system enhances clinical tissue research with Bruker's advanced 10-kHz smartbeam 3D laser, improved imaging detectors, and support for OME-TIFF file output via SCiLS Scope software. The Neoflex MSI system meets the growing need to transition from discovery-focused imaging to clinical implementation.

View the full immunohistochemistry (ihc) market report:
https://www.thebusinessresearchcompany.com/report/immunohistochemistry-ihc-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Core Segmentation of the Global Immunohistochemistry (IHC) Market
This report divides the immunohistochemistry market into several essential segments:
1) By Product: Antibodies, Equipment, Reagents, Kits
2) By Application: Diagnostics, Drug Testing, Other Applications
3) By End-User: Hospitals and Diagnostic Laboratories, Research Institutes, Other End-Users

Further breakdown includes:
• Antibodies: Primary Antibodies, Secondary Antibodies, Conjugated Antibodies
• Equipment: IHC Staining Systems, Slide Scanners, Microscopes
• Reagents: Detection Reagents, Blocking Reagents, Mounting Media
• Kits: Pre-prepared IHC Kits, Multiplex IHC Kits, Specialty Kits

This detailed segmentation helps in understanding the various facets of the IHC market and identifying key areas for investment and development.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.